160P COLUMBIA-1: A phase Ib/II, open-label, randomized, multicenter study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab as first-line (1L) therapy in metastatic microsatellite-stable colorectal cancer (MSS-mCRC)

Subjects

Subjects :

Oncology
Immunology and Allergy

Details

ISSN :

25900188

Volume :

16

Database :

OpenAIRE

Journal :

Immuno-Oncology and Technology

Accession number :

edsair.doi...........03ad663214c20173159525fc5be1be04

Full Text :

https://doi.org/10.1016/j.iotech.2022.100272